Results 41 to 50 of about 413 (135)
, 2023 Contact Dermatitis, Volume 89, Issue 4, Page 299-301, October 2023.
Anna Sophie Quaade +1 more
wiley +1 more source
Dermatoses neutrofílicas: parte II Neutrophilic dermatoses: part II
Anais Brasileiros de Dermatologia, 2011 Neste artigo são abordadas as dermatoses neutrofílicas, complementando o artigo anterior (parte I). São apresentadas e comentadas as seguintes dermatoses: pustulose subcórnea de Sneddon-Wilkinson, dermatite crural pustulosa e atrófica, pustulose ...
Fernanda Razera +2 more
doaj +1 more source
Clinical, Cosmetic and Investigational Dermatology, 2022 Xianjie Yang,* Juan Wang,* Huan Wang, Minmin Kong, Qiquann Chen Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, People’s Republic of China*These authors contributed equally to this workCorrespondence ...
Yang X, Wang J, Wang H, Kong M, Chen Q
doaj
Vaccines, 2022 Clinical and epidemiologic data on pustular psoriasis are scarce. To investigate the phenotypes of pustular psoriasis and the patients’ characteristics observed in a real-life retrospective observational study.
Paolo Gisondi +2 more
doaj +1 more source
Palmoplantar pustulosis: pathogenesis, differential diagnosis, and treatment
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 4, Page 516-535, April 2026.Summary Palmoplantar pustulosis (PPP) is a chronic inflammatory and often painful disease characterized by sterile pustules on the palms and soles, significantly impairing quality of life. Women are more frequently affected than men, and smoking is a major trigger. Under biologic therapies, especially TNF antagonists, a paradoxical PPP may occur.
Rotraut Mössner +5 more
wiley +1 more source
Treatment of acrodermatitis continua of hallopeau with ixekizumab
Journal of Dermatological Treatment, 2019 Acrodermatitis continua of hallopeau (ACH) is a rare chronic inflammatory variant of pustular psoriasis often restricted to the distal portions the digits in the hands and feet. ACH is of a chronic relapsing nature and is invariably recalcitrant to many available topical and systemic anti-psoriatic therapies.
Austinn C. Miller +2 more
openaire +2 more sources
Experimental Dermatology, Volume 35, Issue 3, March 2026.ABSTRACT Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disease characterised by widespread eruption of sterile, macroscopic pustules. Patients with GPP can present with multiple comorbidities that may influence treatment. This study aimed to assess the frequency of psoriasis‐related complications and non–psoriasis‐related ...
Ryuhei Okuyama +10 more
wiley +1 more source
Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
Nepal Journal of Dermatology, Venereology & Leprology, 2022 Introduction: Apremilast, an oral phosphodiesterase-4 inhibitor, decreases the production of pro-inflammatory cytokines including tumour necrosis factor-α, interleukin-12/23, IL-12, IL-2, and interferon-γ; while upregulating the anti-inflammatory ...
Saurabh Bhatia
doaj +3 more sources
Pustular Psoriasis: From Pathophysiology to Treatment
Biomedicines, 2021 Pustular psoriasis (PP) is a clinicopathological entity encompassing different variants, i.e., acute generalized PP (GPP), PP of pregnancy (impetigo herpetiformis), annular (and circinate) PP, infantile/juvenile PP, palmoplantar PP/palmoplantar ...
Giovanni Genovese +5 more
doaj +1 more source
Real‐World Dose Adjustment and Switching of Interleukin‐17/23 Inhibitors for Thai Psoriasis
Dermatology Research and Practice, Volume 2026, Issue 1, 2026.Interleukin (IL)‐17 and IL‐23 inhibitors have transformed psoriasis care, delivering high clearance rates and quality‐of‐life gains. Nevertheless, inadequate response or adverse events can lead to treatment discontinuation or biologic switching. Dose modifications are also commonly implemented in routine practice to optimize efficacy, safety, and cost.
Chayada Chaiyabutr +7 more
wiley +1 more source